16 januari 2012: bron: PLoS One. 2011;6(6):e19881. Epub 2011 Jun 16.

De afgelopen weken is wereldwijd grote beroering ontstaan door fraude van een wetenschapper, Dr. Dipak Das,  met een studie met resveratrol. En daarmee komt resveratrol ook in een dubieus daglicht te staan. Echter een overzichtstudie afgelopen jaar liet nog eens zien dat resveratrol wel degelijk eigenschappen heeft die kunnen helpen kanker te bestrijden c.q. te voorkomen. Klik hier voor een studie abstract over effect van resveratrol bij prostaatkanker. Hier het abstract van de overzichtsstudie, maar als u hier klikt kunt u het volledige studierapport gratis inzien . Onderaan dit artikel staat een referentielijst van 144 studies gedaan met resveratrol. De studies van Dr. Dipak Das uit de lijst zijn dus bljikbaar gemanipuleerd.

What is new for an old molecule? Systematic review and recommendations on the use of resveratrol

PLoS One. 2011; 6(6): e19881.
Published online 2011 June 16. doi:  10.1371/journal.pone.0019881
PMCID: PMC3116821
Copyright This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Ole Vang,1* Nihal Ahmad,2 Clifton A. Baile,3 Joseph A. Baur,4 Karen Brown,5 Anna Csiszar,6 Dipak K. Das,7 Dominique Delmas,8 Carmem Gottfried,9 Hung-Yun Lin,10 Qing-Yong Ma,11 Partha Mukhopadhyay,12 Namasivayam Nalini,13 John M. Pezzuto,14 Tristan Richard,15 Yogeshwer Shukla,16 Young-Joon Surh,17 Thomas Szekeres,18 Tomasz Szkudelski,19 Thomas Walle,20 and Joseph M. Wu21
1Department of Science, System and Models, Roskilde University, Roskilde, Denmark
2Department of Dermatology, University of Wisconsin, Madison, Wisconsin, United States of America
3Department of Animal and Dairy Science, University of Georgia, Athens, Georgia, United States of America
4Department of Physiology and Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
5Department of Cancer Studies and Molecular Medicine, The Biocentre, University of Leicester, Leicester, Great Britain, United Kingdom
6Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
7Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, Connecticut, United States of America
8INSERM U866, University of Burgundy, Dijon, France
9Department of Biochemistry, Postgraduate Programme of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
10Signal Transduction Laboratory, Ordway Research Institute, Albany, New York, United States of America
11Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China
12Laboratory of Physiological Studies, Section on Oxidative Stress Tissue Injury, National Institutes of Health, Rockville, Maryland, United States of America
13Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamil Nadu, India
14College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii, United States of America
15UFR Pharmacie, University of Bordeaux, Villenave d'Ornon, France
16Proteomics Laboratory, Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India
17College of Pharmacy, Seoul National University, Seoul, South Korea
18Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
19Department of Animal Physiology and Biochemistry, August Cieszkowski University of Agriculture, Poznan, Poland
20Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina, United States of America
21Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, United States of America
Jose Vina, Editor
University of Valencia, Spain
* E-mail: ov@ruc.dk
Conceived and designed the experiments: OV. Analyzed the data: OV NA CAB JAB KB AC DKD DD CG H-YL Q-YM PM NN JMP TR YS Y-JS T. Szekeres T. Szkudelski TW JMW. Wrote the paper: OV. Evaluation of the cancer preventive effect: NA KB H-YL NN JMP YS T. Szekeres. Evaluation of the CHD preventive effect: DKD PM JMW. Evaluation of the obesity/diabetes effect: CAB T. Szkudelski. Evaluation of the anti-aging/anti-inflammatory effect: JAB AC Q-YM. Evaluation of the neuroprotective effect: CG TR. Metabolism and pharmacokinetic of resveratrol: DD TW.
Received January 21, 2011; Accepted April 6, 2011.
Resveratrol is a natural compound suggested to have beneficial health effects. However, people are consuming resveratrol for this reason without having the adequate scientific evidence for its effects in humans. Therefore, scientific valid recommendations concerning the human intake of resveratrol based on available published scientific data are necessary. Such recommendations were formulated after the Resveratrol 2010 conference, held in September 2010 in Helsingør, Denmark.
Literature search in databases as PubMed and ISI Web of Science in combination with manual search was used to answer the following five questions: 1Can resveratrol be recommended in the prevention or treatment of human diseases?; 2Are there observed “side effects” caused by the intake of resveratrol in humans?; 3What is the relevant dose of resveratrol?; 4What valid data are available regarding an effect in various species of experimental animals?; 5Which relevant (overall) mechanisms of action of resveratrol have been documented?
The overall conclusion is that the published evidence is not sufficiently strong to justify a recommendation for the administration of resveratrol to humans, beyond the dose which can be obtained from dietary sources. On the other hand, animal data are promising in prevention of various cancer types, coronary heart diseases and diabetes which strongly indicate the need for human clinical trials. Finally, we suggest directions for future research in resveratrol regarding its mechanism of action and its safety and toxicology in human subjects.
1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220. [PubMed]
2. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics and Effect on the Insulin-like Growth Factor Axis. Cancer Res. 2010;70:9003–9011. [PMC free article] [PubMed]
3. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70:7392–7399. [PMC free article] [PubMed]
4. Soleas GJ, Yan J, Goldberg DM. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl. 2001;757:161–172. [PubMed]
5. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36:79–87. [PubMed]
6. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377–1382. [PubMed]
7. Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:182–187.
8. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidem Biomark Prev. 2007;16:1246–1252.
9. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010;49:449–454. [PubMed]
10. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53:7–15. [PubMed]
11. Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol Nutr Food Res. 2008;52:549–557. [PubMed]
12. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 2004;52:935–942. [PubMed]
13. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005;49:495–504. [PubMed]
14. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, Estruch R, Vazquez-Agell M, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem. 2006;52:1373–1380. [PubMed]
15. Vaz-da-Silva M, Loureiro AI, Falcao A, Nunes T, Rocha JF, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46:564–570. [PubMed]
16. Elliott PJ, Walpole S, Morelli L, Lambert PD, Lunsmann W, et al. Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut. 2009;34:291–295.
17. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91:1590–1597. [PubMed]
18. 2010. Resveratrol trials at ClinicalTrial.gov.
19. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2010 DOI: 10.1016/j.numecd.2010.03.003.
20. Stervbo U, Vang O, Bonnesen C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 2007;101:449–457.
21. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342. [PubMed]
22. Juan ME, Vinardell MP, Planas JM. The daily oral administration, of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr. 2002;132:257–260. [PubMed]
23. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82:614–619. [PubMed]
24. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;49:2170–8221. [PubMed]
25. Hebbar V, Shen GX, Hu R, Kim BR, Chen C, et al. Toxicogenomics of resveratrol in rat liver. Life Sci. 2005;76:2299–2314. [PubMed]
26. Whitsett TG, Jr, Carpenter DM, Lamartiniere CA. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog. 2006;5:15. [PMC free article] [PubMed]
27. Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, et al. Oncogenicity evaluation of resveratrol in p53(+/−) (p53 knockout) mice. Food Chem Toxicol. 2007;45:55–63. [PMC free article] [PubMed]
28. Wong YT, Gruber J, Jenner AM, Ng MP, Ruan R, et al. Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Radic Biol Med. 2009;46:799–809. [PubMed]
29. Watzl B, Bub A, Pretzer G, Roser S, Barth SW, et al. Daily moderate amounts of red wine or alcohol have no effect on the immune system of healthy men. Eur J Clin Nutr. 2004;58:40–45. [PubMed]
30. Watzl B, Bub A, Briviba K, Rechkemmer G. Acute intake of moderate amounts of red wine or alcohol has no effect on the immune system of healthy men. Eur J Nutr. 2002;41:264–270. [PubMed]
31. Vazquez-Agell M, Sacanella E, Tobias E, Monagas M, Antunez E, et al. Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J Nutr. 2007;137:2279–2284. [PubMed]
32. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–661. [PubMed]
33. Kapadia GJ, Azuine MA, Tokuda H, Takasaki M, Mukainaka T, et al. Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res. 2002;45:499–505. [PubMed]
34. Soleas GJ, Grass L, Josephy PD, Goldberg DM, Diamandis EP. A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin Biochem. 2002;35:119–124. [PubMed]
35. Yusuf N, Nasti TH, Meleth S, Elmets CA. Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinogen. 2009;48:713–723.
36. Roy P, Kalra N, Prasad S, George J, Shukla Y. Chemopreventive Potential of Resveratrol in Mouse Skin Tumors Through Regulation of Mitochondrial and PI3K/AKT Signaling Pathways. Pharm Res. 2009;26:211–217. [PubMed]
37. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, et al. Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr. 2006;136:2542–2546. [PMC free article] [PubMed]
38. Kowalczyk MC, Kowalczyk P, Tolstykh O, Hanausek M, Walaszek Z, et al. Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res. 2010;3:170–178.
39. Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, et al. Effect of Resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2005;115:36–45. [PubMed]
40. El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM, Darweish MM. Prominent chemopreventive and chemoenhancing effects for resveratrol: unraveling molecular targets and the role of C-reactive protein. Chemotherapy. 2010;56:60–65. [PubMed]
41. Bove K, Lincoln DW, Tsan MF. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2002;291:1001–1005. [PubMed]
42. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 2001;61:7456–7463. [PubMed]
43. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002;62:4945–4954. [PubMed]
44. Sato M, Pei RJ, Yuri T, Danbara N, Nakane Y, et al. Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett. 2003;202:137–145. [PubMed]
45. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact. 2009;179:131–144. [PubMed]
46. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med. 2002;33:387–398. [PubMed]
47. Yu L, Sun ZJ, Wu SL, Pan CE. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol. 2003;9:2341–2343. [PubMed]
48. Liu HS, Pan CE, Yang W, Liu XM. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 2003;9:1474–1476. [PubMed]
49. Woodall CE, Li Y, Liu QH, Wo J, Martin RC. Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anti Cancer Drug. 2009;20:437–443.
50. Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol. 2005;11:280–284. [PubMed]
51. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer. 2004;91:1742–1750. [PMC free article] [PubMed]
52. Sengottuvelan M, Nalini N. Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr. 2006;96:145–153. [PubMed]
53. Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis. 2000;21:1619–1622. [PubMed]
54. Kineman BD, Au A, Paiva NL, Kaiser MS, Brummer EC, et al. Transgenic alfalfa that accumulates piceid (Trans-Resveratrol-3-O-Beta-D-glucopyranoside) requires the presence of beta-glucosidase to inhibit the formation of aberrant crypt foci in the colon of CF-1 mice. Nutr Cancer. 2007;58:66–74. [PubMed]
55. Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res. 2010;3:549–559.
56. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, et al. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer. 2001;39:102–107. [PubMed]
57. Ziegler CC, Rainwater L, Whelan J, McEntee MF. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr. 2004;134:5–10. [PubMed]
58. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, et al. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer. 2005;115:194–201. [PubMed]
59. Harper CE, Cook LM, Patel BB, Wang J, Eltoum IA, et al. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate. 2009;69:1668–1682. [PMC free article] [PubMed]
60. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev. 2008;9:7–14. [PubMed]
61. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer. 2009;125:1–8. [PubMed]
62. Wang TT, Hudson TS, Wang TC, Remsberg CM, Davies NM, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. 2008;29:2001–2010. [PMC free article] [PubMed]
63. Hecht SS, Kenney PM, Wang M, Trushin N, Agarwal S, et al. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett. 1999;137:123–130. [PubMed]
64. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000;87:595–600. [PubMed]
65. Kimura Y, Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr. 2001;131:1844–1849. [PubMed]
66. Berge G, Ovrebo S, Eilertsen E, Haugen A, Mollerup S. Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo pyrene. Br J Cancer. 2004;91:1380–1383. [PMC free article] [PubMed]
67. Chen Y, Tseng SH, Lai HS, Chen WJ. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery. 2004;136:57–66. [PubMed]
68. Behbahani J, Thandapilly SJ, Louis XL, Huang Y, Shao Z, et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens. 2010;23:1273–1278. [PubMed]
69. Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010;23:192–196. [PubMed]
70. Chan V, Fenning A, Iyer A, Hoey A, Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol. 2011;12:429–436. [PubMed]
71. Yang DL, Zhang HG, Xu YL, Gao YH, Yang XJ, et al. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol. 2010;37:150–155. [PubMed]
72. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009;54:668–675. [PMC free article] [PubMed]
73. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77:1053–1063. [PubMed]
74. Sutra T, Oiry C, zay-Milhau J, Youl E, Magous R, et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: Involvement of osteopontin and oxidative stress. J Agric Food Chem. 2008;56:11683–11687. [PubMed]
75. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, et al. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens. 2005;18:864–870. [PubMed]
76. Aubin MC, Lajoie C, Clement R, Gosselin H, Calderone A, et al. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther. 2008;325:961–968. [PubMed]
77. Chen YR, Yi FF, Li XY, Wang CY, Chen L, et al. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther. 2008;22:479–485. [PubMed]
78. Lin JF, Lin SM, Chih CL, Nien MW, Su HH, et al. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci. 2008;83:313–317. [PubMed]
79. Burstein B, Maguy A, Clement R, Gosselin H, Poulin F, et al. Effects of resveratrol (trans-3,5,4′-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J Pharmacol Exp Ther. 2007;323:916–923. [PubMed]
80. Fukuda S, Kaga S, Zhan L, Bagchi D, Das DK, et al. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys. 2006;44:43–49. [PubMed]
81. Wojciechowski P, Juric D, Louis XL, Thandapilly SJ, Yu L, et al. Resveratrol arrests and regresses the development of pressure overload - but not volume overload-induced cardiac hypertrophy in rats. J Nutr. 2010;140:962–968. [PubMed]
82. Saleh MC, Connell BJ, Saleh TM. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors. Neuroscience. 2010;166:445–454. [PubMed]
83. Huang JP, Huang SS, Deng JY, Chang CC, Day YJ, et al. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med. 2010;49:1710–1721. [PubMed]
84. Lekli I, Szabo G, Juhasz B, Das S, Das M, et al. Protective mechanisms of resveratrol against ischemia/reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol. 2007;294:H859–H866. [PubMed]
85. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med. 2007;43:720–729. [PMC free article] [PubMed]
86. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem. 2009;20:443–452. [PubMed]
87. Das S, Tosaki A, Bagchi D, Maulik N, Das DK. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther. 2006;317:980–988. [PubMed]
88. Robich MP, Osipov RM, Nezafat R, Feng J, Clements RT, et al. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation. 2010;122:S142–S149. [PMC free article] [PubMed]
89. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122. [PubMed]
90. Dal-Pan A, Blanc S, Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol. 2010;10:11. [PMC free article] [PubMed]
91. Macarulla MT, Alberdi G, Gomez S, Tueros I, Bald C, et al. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem. 2009;65:369–376. [PubMed]
92. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMPactivated protein kinase. Acta Pharmacol Sin. 2008;29:698–706. [PubMed]
93. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008;8:40. [PMC free article] [PubMed]
94. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother. 2008;62:598–605. [PubMed]
95. Gonzalez-Rodriguez A, Mas Gutierrez JA, Sanz-Gonzalez S, Ros M, Burks DJ, et al. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes. 2010;59:588–599. [PMC free article] [PubMed]
96. Um JH, Park SJ, Kang H, Yang S, Foretz M, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59:554–563. [PMC free article] [PubMed]
97. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, et al. Central administration of resveratrol improves diet-induced diabetes. Endocrinology. 2009;150:5326–5333. [PMC free article] [PubMed]
98. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712–716. [PMC free article] [PubMed]
99. Rocha KK, Souza GA, Ebaid GX, Seiva FR, Cataneo AC, et al. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol. 2009;47:1362–1367. [PubMed]
100. Kim YH, Kim YS, Kang SS, Cho GJ, Choi WS. Resveratrol inhibits neuronal apoptosis and elevated Ca2+/calmodulin-dependent protein kinase II activity in diabetic mouse retina. Diabetes. 2010;59:1825–1835. [PMC free article] [PubMed]
101. Akar F, Pektas MB, Tufan C, Soylemez S, Sepici A, et al. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther. 2011 DOI: 10.1007/s10557-010-6255-7.
102. Kiziltepe U, Turan NN, Han U, Ulus AT, Akar F. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J Vasc Surg. 2004;40:138–145. [PubMed]
103. Yang YB, Piao YJ. Effects of resveratrol on secondary damages after acute spinal cord injury in rats. Acta Pharmacol Sin. 2003;24:703–710. [PubMed]
104. Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002;71:655–665. [PubMed]
105. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, et al. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci. 2007;14:256–260. [PubMed]
106. Mokni M, Elkahoui S, Limam F, Amri M, Aouani E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res. 2007;32:981–987. [PubMed]
107. Robb EL, Winkelmolen L, Visanji N, Brotchie J, Stuart JA. Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochem Biophys Res Commun. 2008;372:254–259. [PubMed]
108. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, et al. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem. 2007;294:137–144. [PubMed]
109. Wang Q, Yu S, Simonyi A, Rottinghaus G, Sun GY, et al. Resveratrol protects against neurotoxicity induced by kainic acid. Neurochem Res. 2004;29:2105–2112. [PubMed]
110. Tsai SK, Hung LM, Fu YT, Cheng H, Nien MW, et al. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J Vasc Surg. 2007;46:346–353. [PubMed]
111. Karuppagounder SS, Pinto JT, Xu H, Chen LH, Beal MF, et al. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009;54:111–118. [PMC free article] [PubMed]
112. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, et al. Effects of resveratrol and methylprednisolone on biochemical, neurobehavioral and histopathological recovery after experimental spinal cord injury. Acta Pharmacol Sin. 2006;27:1317–1325. [PubMed]
113. Yousuf S, Atif F, Ahmad M, Hoda N, Ishrat T, et al. Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res. 2009;1250:242–253. [PubMed]
114. Lu KT, Chiou RY, Chen LG, Chen MH, Tseng WT, et al. Neuroprotective effects of resveratrol on cerebral ischemia-induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation. J Agric Food Chem. 2006;54:3126–3131. [PubMed]
115. Sakata Y, Zhuang H, Kwansa H, Koehler RC, Dore S. Resveratrol protects against experimental stroke: Putative neuroprotective role of heme oxygenase 1. Exp Neurol. 2010;224:325–329. [PMC free article] [PubMed]
116. Della-Morte D, Dave KR, Defazio RA, Bao YC, Raval AP, et al. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1 – uncoupling protein 2 pathway. Neuroscience. 2009;159:993–1002. [PMC free article] [PubMed]
117. Wu Z, Xu Q, Zhang L, Kong D, Ma R, et al. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res. 2009;34:1393–1400. [PubMed]
118. Lu KT, Ko MC, Chen BY, Huang JC, Hsieh CW, et al. Neuroprotective Effects of Resveratrol on MPTP-Induced Neuron Loss Mediated by Free Radical Scavenging. J Agric Food Chem. 2008;56:6910–6913. [PubMed]
119. Sonmez U, Sonmez A, Erbil G, Tekmen I, Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett. 2007;420:133–137. [PubMed]
120. Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE. Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma. 2010;27:1091–1099. [PMC free article] [PubMed]
121. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010;1328:139–151. [PubMed]
122. Binienda ZK, Beaudoin MA, Gough B, Ali SF, Virmani A. Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl-L-carnitine and resveratrol. Neurosci Lett. 2010;480:117–121. [PubMed]
123. Kumar P, Padi SS, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol. 2006;17:485–492. [PubMed]
124. Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: A probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun. 2010;394:360–365. [PubMed]
125. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007;26:3169–3179. [PMC free article] [PubMed]
126. Ranney A, Petro MS. Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav Pharmacol. 2009;20:330–336. [PubMed]
127. Oomen CA, Farkas E, Roman V, van der Beek EM, Luiten PG, et al. Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front Aging Neurosci. 2009;1:4.:4. [PMC free article] [PubMed]
128. Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, et al. Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res Bull. 2009;80:371–376. [PubMed]
129. Kumar A, Naidu PS, Seghal N, Padi SS. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology. 2007;79:17–26. [PubMed]
130. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008;600:78–82. [PubMed]
131. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress. Am J Physiol Heart Circ Physiol. 2010;299:H985–H994. [PMC free article] [PubMed]
132. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol. 2010;224:423–432. [PubMed]
133. Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res. 2007;21:278–283. [PubMed]
134. Larrosa M, Yanez-Gascon MJ, Selma MV, Gonzalez-Sarrias A, Toti S, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem. 2009;57:2211–2220. [PubMed]
135. Larrosa M, Tome-Carneiro J, Yanez-Gascon MJ, Alcantara D, Selma MV, et al. Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem. 2010;53:7365–7376. [PubMed]
136. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 2010;633:78–84. [PubMed]
137. Singh UP, Singh NP, Singh B, Hofseth LJ, Price RL, et al. Resveratrol (trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther. 2010;332:829–839. [PMC free article] [PubMed]
138. Yao J, Wang JY, Liu L, Li YX, Xun AY, et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res. 2010;41:288–294. [PubMed]
139. Inanaga K, Ichiki T, Matsuura H, Miyazaki R, Hashimoto T, et al. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens Res. 2009;32:466–471. [PubMed]
140. Tunali-Akbay T, Sehirli O, Ercan F, Sener G. Resveratrol protects against methotrexate-induced hepatic injury in rats. J Pharm Pharm Sci. 2010;13:303–310. [PubMed]
141. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, Wolin MS, et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol. 2008;294:H2721–H2735. [PMC free article] [PubMed]
142. Sener G, Topaloglu N, Ozer SA, Ercan F, Gedik N. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm Pharmacol Ther. 2007;20:642–649. [PubMed]
143. Hong SW, Jung KH, Zheng HM, Lee HS, Suh JK, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Research. 2010;33:601–609. [PubMed]
144. Sengottuvelan M, Deeptha K, Nalini N. Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition. 2009;25:1169–1176. [PubMed]
145. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol. 2006;147:873–885. [PMC free article] [PubMed]

Plaats een reactie ...

Reageer op "Resveratrol - een stofje met anti kanker werking staat ter discussie door fraude van 1 wetenschapper, maar overzichtstudie toont aan dat resveratrol wel degelijk anti kanker eigenschappen heeft"

Gerelateerde artikelen

Gerelateerde artikelen

Alternatieve therapieën bij >> Algemene artikelen over complementaire >> Ayurvedische kruiden en middelen >> Voorlichtingsfilmpjes over >> Agaricus Blazei Murill een >> Aids - HIV en effect van voeding >> Aldara zalf - Imiquimod, een >> Aloe Vera naast chemo bij >> AMAS test - Anti Maligne Antibody >> Antioxidanten, voeding en >>